Skip to main content

Protective Benefit of Colchicine in COVID-19 Infection

Jun 26, 2020 11:35 am

Colchicine has been advocated as a potential antiinflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had less clinical deterioration without significant changes in biomarkers, such as high-sensitivity cardiac troponin and C-reactive protein.

The GRECCO study was a prospective, open-label, randomized clinical trial of 105 patients hospitalized with COVID-19 who were randomized 1:1 to either
colchicine (1.5-mg loading dose followed by 0.5 mg twice daily) or placebo on a background of standard medical treatment. The primary end points were (1) maximum high-sensitivity cardiac troponin; (2) C-reactive protein; and (3) time to deterioration by 2 points (7-grade clinical status scale)

Patients were 58% male, mean age of 64 years).  Enpoint outcomes were as shown below:

Clinical Outcomes in GRECCO Trial
  Colchicine Control p Value
hs cardiac troponin (ng/ml) 0.008 0.0112 P = 0.34
C-reactive protein (mg/dl) 3.1 4.5 P = 0.73
Primary Clinical endpoint 1.8% 14% P = 0.02
Event-free survival (days) 20.7 18.6  P = 0.03

Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P = .003).

In this randomized clinical trial, those who received colchicine had a longer time to clinical deterioration.

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×